Amgen has had a notable quarter, exhibiting an array of wins and losses. Despite reporting a beat for its
Q2 2024 results, the company's shares went down, possibly due to a fall in the broader market or a reduction in its projected earnings. Nevertheless,
Amgen displays a solid standing in the
obesity market, showing promising developments in obesity medication, which underscores its
long-term growth prospects. Adjustments in its projected 2024 earnings and shareholder dividends are drawing investors' attention. Despite an EPS miss, the bio-tech giant maintains strong confidence in their weight-loss drug,
MariTide. A dip in stock price, occurring concurrently with robust Q2 results, suggests that these stocks may still hold value for savvy investors. Moving ahead,
Amgen anticipates potential hurdles, backed by its resiliency, offering hopeful future outcomes for shareholders.
Amgen AMGN News Analytics from Thu, 09 Nov 2023 06:15:22 GMT to Sun, 11 Aug 2024 13:48:36 GMT -
Rating 4
- Innovation 7
- Information 9
- Rumor -3
